
 
 
 
 
 
 
 
 
   
 THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 
 1. A compound of formula III: 
 or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 R 22  is selected from: 
 (a) formula IVa: 
 'Prat 
 IVa wherein A is a C 5 . 7  aryl group, and either (i) O 1  is a single bond, and O 2  is selected from a single bond and -Z-(CH 2 ) n  , where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) O 1  is -CH=CH-, and O 2  is a single bond; 
 (b) formula IVb: 
 R C2  wherein R C1 , R C2  and R C3  are independently selected from H and unsubstituted C-i_ 2  alkyl; 
 (c) formula IVc: 
 20 L 4  is selected from a single bond and a group of: 
 (a): 
 218 
 2013366490 24 Nov 2017 wherein n is 0 to 3; (b) (c) , wherein n is as defined above; 
 (d) , wherein n is as defined above; and  
 , wherein n is as defined above, E is O, S or NR, D is N, CH, or CR, and F is N, CH, or CR; 
 L 3  is: 
   X x A, 
 N ' Prot H  0  , where X is such that L 3  is an amino-acid residue, a dipeptide residue or a tripeptide residue; 
 Prot is selected from Fmoc (fluorenylmethyloxycarbonyl), Teoc ( 
 
     
 2(trimethylsilyl)ethoxycarbonyl) and Boc (t-butoxycarbonyl); 
 and either: 
 when there is a double bond present between C2’ and C3’, R 12  is selected from the group consisting of: 
 (ia) C 5 . 10  aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, Cp alkyl, C 3 . 7  heterocyclyl and bis-oxy-C^ alkylene; 
 (ib) Ci- 5  saturated aliphatic alkyl; 
 (ic) C 3 - 6  saturated cycloalkyl; 
 219 
 2013366490 24 Nov 2017 , wherein each of R 21 , R 22  and R 23  are independently selected from H, C-i_ 3  saturated alkyl, C 2 - 3  alkenyl, C 2 . 3  alkynyl and cyclopropyl, where the total number of carbon atoms in the R 12  group is no more than 5; 
 ,25b 
 R' 
 25a wherein one of R 25a  and R 25b  is H and the other is selected from: 
 (ie) phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and (if)  K  , where R 24  is selected from: H; Ci_ 3  saturated alkyl; C 2 . 3  alkenyl; C 2 . 3  alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; 
 when there is a single bond present between C2’ and C3’, ,26 a 
 R 12  is H or  R  , where R 26a  and R 26b  are independently selected from H, F, C M  saturated alkyl, C 2 . 3  alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C« alkyl amido and C« alkyl ester; or, when one of R 26a  and R 26b  is H, the other is selected from nitrile and a C1-4 alkyl ester; 
 R 6  and R 9  are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR’, nitro, Me 3 Sn and halo; 
 where R and R’ are independently selected from optionally substituted C-i_i 2  alkyl, C 3 . 20  heterocyclyl and C5-20 aryl groups; 
 R 7  is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NHRR’, nitro, Me 3 Sn and halo; 
 R is a C 3 _i 2  alkylene group, which chain is interrupted by one or more aromatic rings, e.g. benzene or pyridine; 
 Y and Y’ are selected from O, S, or NH; 
 R 6 , R 7 , R 9  are selected from the same groups as R 6 , R 7  and R 9  respectively; 
 either: 
 (A) R 20  is H or Me and R 21a  and R 21b  are both H or together form =0 and either: 
 (i) R 10  is H, R 11a  is H and R 11b  is OH or OR A , where R A  is C-m alkyl; or (ii) R 10  and R 11b  form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound and R 11a  is H; or 
 220 
 2013366490 24 Nov 2017 (iii) R 10  is H, R 11a  is H and R 11b  is SO Z M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; or (B) R 10  is H or Me and R 11a  and R 11b  are both H or together form =0 and either: 
 (i) R 20  is H, R 21a  is H and R 21b  is OH or OR A , where R A  is alkyl; or (ii) R 20  and R 21b  form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound and R 11a  is H; or (iii) R 20  is H, R 21a  is H and R 21b  is SO Z M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation. 
 
     
 3 2. A compound according to any claim 1, wherein R 7  is a Ci_ 
 
     
 4 alkyloxy group. 
 3. A compound according to either claim 1 or claim 2, wherein Y is O and R” is C 3 . 7  alkylene. 
 
     
 5 4. A compound according to any one of claims 1 to 3, wherein R 6  and R 9  are H. 
 5. A compound according to any one of claims 1 to 4, wherein there is a double bond between C2’ and C3’, and R 12  is: 
 (a) a C 5 . 7  aryl group, which may bear one to three substituent groups selected from 
 3 methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl; or (b) methyl, ethyl or propyl; or (c) cyclopropyl; or (d) a group of formula: 
 R' ,22 
 R' ,23 , wherein the total number of carbon atoms in the R 12  group is no more than 4; 
 or (e) the group: 
 ; or (f) a group of formula: 
   R  , wherein R 24  is selected from H and methyl. 
 221 
 2013366490 24 Nov 2017 
 
     
 6. 
 A compound according to any one of claims 1 to 4, wherein there is a single bond 
 R 26a  between C2’ and C3’, R 12  is  R  and: 
 (a) R 26a  and R 26b  are both H; or (b) R 26a  and R 26b  are both methyl; or (c) one of R 26a  and R 26b  is H, and the other is selected from C-m saturated alkyl, C 2 -3 alkenyl, which alkyl and alkenyl groups are optionally substituted. 
 
     
 7. A compound according to any one of claims 1 to 6, wherein R 2  is of formula Ila, and 3 A is phenyl, Q 1  is a single bond, and Q 2  is a single bond. 
 
     
 8. A compound according to any one of claims 1 to 6, wherein R 2  is of formula lib, and R C1 , R C2  and R C3  are all H. 
 5 
 
     
 9. A compound according to either claim 7 or claim 8, wherein X is NH 2 . 
 
     
 10. A compound according to any one of claims 1 to 6, wherein R 2  is of formula lie, and Q is NR n , wherein R N  is H or methyl. 
 3 
 
     
 11. A compound according to any one of claims 1 to 10, wherein R 6 , R 7 , R 9  and Y’ are the same as R 6 , R 7 , R 9 , and Y respectively. 
 
     
 12. A compound according to any one of claims 1 to 11, wherein R 20  is H or Me and R 21a  and R 21b  are both H. 
 
     
 13. A compound according to any one of claims 1 to 12, wherein R 20  is H or Me and R 21a  and R 21b  together form =0. 
 
     
 14. A compound according to either claim 12 or claim 13, wherein R 10  and R 11b  form a 30 nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound and R 11a  is H. 
 
     
 15. A compound according to any one of claims 1 to 11, wherein R 10  is H or Me and R 11a  and R 11b  are both H. 
 222 
 2013366490 24 Nov 2017 
 
     
 16. A compound according to any one of claims 1 to 11, wherein R 10  is H or Me and R 11a  and R 11b  together form =0. 
 5 
 
     
 17. A compound according to either claim 15 or claim 16, wherein R 20  and R 21b  form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound and R 11a  is H. 
 
     
 18. The use of a compound according to any one of claims 1 to 17 in the manufacture 3 of a medicament for treating a proliferative disease. 
 
     
 19. A method of treating a mammal having a proliferative disease, comprising administering an effective amount of a compound according to any one of claims 1 to 17. 
 5 
 
     
 20. A conjugate comprising a compound of formula I according to any one of claims 1 to 17, or a pharmaceutically acceptable salt or solvate thereof, linked to a targeting agent. 
 
     
 21. A Conjugate having formula V: 
 L-(LU-D) P  (V) wherein L is an antibody or antibody fragment, p is 1 to 20; and 
 D is a Drug unit which is a PBD dimer according to formula I: 
 R 12 , R 20 , wherein R 6 , R 6 , R 7 , R 7 , R 9 , R 9 , R 10 , R 11a , R 11b , defined in any one of claims 1 to 17; and R 2  is of formula Ila, formula lib or formula lie: 
 R 21a , R 21b , Y, Y’ and R” are as (a/a’-'V* Ila where A is a C 5 . 7  aryl group, and either (i) Q 1  is a single bond, and Q 2  is selected from a single bond and -Z-(CH 2 ) n -, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or 
 223 
 2013366490 24 Nov 2017 (ii) Q 1  is -CH=CH-, and Q 2  is a single bond; 
 where; 
 R C1 , R C2  and R C3  are independently selected from H and unsubstituted C-i_ 2  alkyl; 
 (c) where Q is selected from OH, SH and NR n , and R N  is selected from H, methyl and ethyl X is selected from the group comprising: OH, SH, CO 2 H, COH, N=C=O, NHNH 2 , 
 NH 
 CONHNH 2 , , NHR n , wherein R N  is selected from the group comprising H and C 14  alkyl; 
 wherein LU is connected to D via the X substituent of R 2 , wherein LU has the formula (Va): 
 -A 1 a-L 1 s-L 2 y-, (Va) wherein: 
 a is 1 or 2, 
 5 s is an integer ranging from 0 to 12, y is 0, 1 or 2, and p is from 1- 20; 
 L 1  comprises an amino acid sequence; 
 L 2  is selected from the groups 
 O 
 224 
 Γο 
 CM > 
 Ο 
 Ζ 
 CM 
 Ο 
 Ok kO kO 
 CO 
 CO o 
 CM wherein the asterisk indicates the point of attachment to the Drug unit, and the wavy line indicates the point of attachment to L 1 , 
 Y is -N(H)-, -0-, -C(=0)N(H)- or-0(=0)0-, n is 0 to 3 
 EisO, SorNH, 
 D is N orCH, 
 F is N orCH; 
 -A 1 - is selected from where the asterisk indicates the point of attachment to L 1 , the wavy line indicates the point of attachment to L, and n is 0 to 6; 
 225 
 2013366490 24 Nov 2017 where the asterisk indicates the point of attachment to L 1 , the wavy line indicates the point of attachment to L, and n is 0 to 6; 
 where the asterisk indicates the point of attachment to L 1 , the wavy line indicates the point of attachment to L, n is 0 or 1, and m is 0 to 30; or where the asterisk indicates the point of attachment to L 1 , the wavy line indicates the point of attachment to L, n is 0 or 1, and m is 0 to 30. 
 
     
 22. The use of a Conjugate according to claim 20 or 21, in the manufacture of a medicament for treating a proliferative disease or an autoimmune disease. 
 
     
 23. A method of treating a mammal having a proliferative disease or an autoimmune disease, comprising administering an effective amount of the Conjugate of claim 20 or claim 21. 
 
     
 24. A drug linker of formula VI: 
 LU-D (VI) or a pharmaceutically acceptable salt or solvate thereof, wherein D is a Drug unit which is a PBD dimer according to formula I as defined in claim 21, but where X is selected from *-Oq, *_ s _q, *. C o 2 .q i  *-CO- q , *-NH(C=O)- q , *-NHNH- q , *-CONHNH- q , 
 226 
 2013366490 24 Nov 2017 
 -Ν 
 N-£- *—N(R n )\-/ ,  p  , wherein R N  is selected from the group comprising H and 
 C1-4 alkyl, and the asterix indicates the point of attachment to the remainder of the Drug unit and the wavy line or q  indicates the point of attachment to LU; 
 wherein LU is selected from: 
 G 1 -L 1 -L 2 - and wherein L 1  and L 2  are as defined in claim 21; 
 and -G 1 - is selected from 
 O 
 N L Jn 
 7) where the asterisk indicates the point of attachment to L 1  and n is 0 to 6; O 'N' 
 O 
 O where the asterisk indicates the point of attachment to L 1  and n is 0 to 6; 
 where the asterisk indicates the point of attachment to L 1 , n is 0 or 1, and m is 0 to 
 30; or 
 O 
 227 
 2013366490 24 Nov 2017 where the asterisk indicates the point of attachment to L 1 , n is 0 or 1, and m is 0 to 30 
 
   
 
 
 
 
 
 
 
 
